Medication info
Statjet Tablet 4/10 mg (Pitavastatin Calcium, Ezetimibe)

Statjet Tablet 4/10 mg (Pitavastatin Calcium, Ezetimibe)

Prescription medicationTabletOral
Ingredient · strength
Pitavastatin Calcium›4mg / 1 tabletEzetimibe›10mg / 1 tablet
Manufacturer / importer
Hanlim Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202301667 · Approved 2023.05.25 · Insurance code 645306970

Summary

Main use
Improvement of primary hypercholesterolemia and mixed dyslipidemia
Who takes it
Adults
Adult dose
Administer this medicine once daily, regardless of meals. Patients should continue to follow a standard cholesterol-lowering diet before and during treatment with this medicine. The dose of this medicine should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment goal, and response. The recommended initial dose is 2/10mg once daily. If the reduction in LDL cholesterol is insufficient, the dose may be increased up to a maximum of 4/10mg daily. Adjust the dose as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response. Patients taking pitavastatin calcium and ezetimibe concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Administration in patients with hepatic impairment: Because an initial dose of 1 milligram of pitavastatin calcium is recommended for patients with hepatic impairment, this medicine (a combination of pitavastatin calcium/ezetimibe) is not recommended for initial treatment. The maximum dose is 2/10mg daily. Use of this medicine (a combination of pitavastatin calcium/ezetimibe) is not recommended in patients with moderate hepatic impairment. Do not administer this medicine (a combination of pitavastatin calcium/ezetimibe) to patients with severe hepatic impairment.

Ingredients

Manufacturer
Hanlim Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of primary hypercholesterolemia and mixed dyslipidemia

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • non-familial hypercholesterolemia
  • mixed dyslipidemia
  • elevated total cholesterol
  • elevated LDL cholesterol
  • elevated apo B protein
  • elevated triglycerides
  • elevated non-HDL cholesterol
View approved original text

This medication helps reduce total cholesterol, LDL cholesterol, apo B, triglycerides, and non-HDL cholesterol levels in patients with primary hypercholesterolemia or mixed dyslipidemia, while increasing HDL cholesterol levels. It is used as an adjunct to dietary management, aiding in the improvement of blood lipid levels to maintain a healthy vascular state.

How to take

Adult dose

Administer this medicine once daily, regardless of meals. Patients should continue to follow a standard cholesterol-lowering diet before and during treatment with this medicine. The dose of this medicine should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment goal, and response. The recommended initial dose is 2/10mg once daily. If the reduction in LDL cholesterol is insufficient, the dose may be increased up to a maximum of 4/10mg daily. Adjust the dose as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response. Patients taking pitavastatin calcium and ezetimibe concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Administration in patients with hepatic impairment: Because an initial dose of 1 milligram of pitavastatin calcium is recommended for patients with hepatic impairment, this medicine (a combination of pitavastatin calcium/ezetimibe) is not recommended for initial treatment. The maximum dose is 2/10mg daily. Use of this medicine (a combination of pitavastatin calcium/ezetimibe) is not recommended in patients with moderate hepatic impairment. Do not administer this medicine (a combination of pitavastatin calcium/ezetimibe) to patients with severe hepatic impairment.

Precautions

This drug should not be used in patients with allergies or history of hypersensitivity to certain components. It is also contraindicated in patients with active liver disease or unexplained elevation of liver enzyme levels, severe liver impairment, or biliary obstruction. Patients taking cyclosporine, those with myopathy, pregnant women or women who may become pregnant, nursing mothers, and children should not use this medication. This drug contains lactose, so it should not be administered to patients with lactose intolerance or related genetic disorders. Caution should be exercised when administering to patients with mild to moderate liver function impairment, excessive alcohol consumption, renal impairment, hypothyroidism, and the elderly. Particularly, patients taking fibrates or niacin are at higher risk for muscle-related side effects, and it is advisable to avoid concomitant administration of these medications if possible. While using this drug, any muscle-related symptoms such as myalgia, weakness, or muscle tenderness should lead to prompt consultation with a physician, and liver function tests should be performed regularly. Serious muscle-related side effects such as myopathy or rhabdomyolysis can occur, and if such symptoms are suspected, the medication should be discontinued immediately. If signs of impaired liver function appear, treatment should be halted, and appropriate measures should be taken, including regular blood tests to monitor liver enzyme levels. This medication is not to be used in pregnant or nursing women, and women planning to become pregnant should consult a physician before use. Safety and efficacy in children have not been established, thus it should not be used in pediatric patients. In the elderly, dosage adjustment is generally not necessary, but caution is required in case of adverse reactions. If an overdose occurs, there is no specific antidote, and treatment should be symptomatic and supportive, with monitoring of liver function and muscle-related tests. This medication should be kept out of reach of children and should not be transferred to another container to maintain quality.

Side effects

  • Abdominal pain
  • diarrhea
  • dry mouth
  • bloating
  • gastroesophageal reflux disease
  • toothache
  • increased serum creatine phosphokinase
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • asthenia
Show 109 more
  • chest discomfort
  • fatigue
  • myalgia
  • dysgeusia
  • headache
  • urticaria
  • dizziness
  • decreased appetite
  • insomnia
  • dyspnea
  • constipation
  • contact dermatitis
  • lightheadedness
  • sensory impairment
  • myopathy
  • liver dysfunction
  • jaundice
  • thrombocytopenia
  • rash
  • pruritus
  • erythema
  • angioedema
  • increased bilirubin
  • increased cholinesterase
  • increased γ-GT
  • increased ALP
  • increased LDH
  • rigidity
  • drowsiness
  • thirst
  • dyspepsia
  • abdominal distension
  • stomatitis
  • vomiting
  • anorexia
  • glossitis
  • nausea
  • gastrointestinal discomfort
  • thrombocytopenia
  • granulocytopenia
  • leukopenia
  • eosinophilia
  • leukocytosis
  • increased globulin
  • positive Coombs test
  • anemia
  • polyuria
  • increased BUN
  • increased serum creatinine
  • decreased aldosterone
  • increased aldosterone
  • increased adrenocorticotropic hormone
  • increased cortisol
  • decreased testosterone
  • muscle cramps
  • increased myoglobin
  • palpitations
  • skin pain
  • burning sensation
  • arthralgia
  • edema
  • blurred vision
  • photophobia
  • hearing loss
  • hematuria
  • increased uric acid levels
  • hair loss
  • sleep disturbances
  • memory loss
  • depression
  • interstitial lung disease
  • sexual dysfunction
  • diabetes
  • immune-mediated necrotizing myopathy
  • facial edema
  • arm edema
  • hypersensitivity
  • paresthesia
  • increased blood pressure
  • chest discomfort
  • upper respiratory tract infection
  • pharyngitis
  • sinusitis
  • cough
  • arthralgia
  • low back pain
  • limb pain
  • congestive heart failure
  • myocardial ischemia
  • flushing
  • conjunctival hyperemia
  • renal failure
  • abnormal liver function
  • increased serum creatinine
  • increased serum urea
  • xerostomia
  • epigastric discomfort
  • belching
  • gastrointestinal disorders
  • gastritis
  • cholelithiasis
  • cholecystitis
  • pancreatitis
  • tremors
  • diabetic neuropathy
  • anemia
  • splenomegaly
  • hyperhidrosis
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that protects it from light. Furthermore, to maintain the effectiveness of the drug, it is important to store it at a temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Pink oval film-coated tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.